Idiotype vaccination for Non-Hodgkin lymphoma

Ossendorf, Vera; Cornely, Oliver A.; Draube, Andreas; Monsef, Ina; Engert, Andreas; Skoetz, Nicole

doi:10.1002/14651858.cd008964

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ossendorf et al published a very similar Cochrane protocol in 2011 dedicated to idiotype vaccination for non-Hodgkin lymphoma (Ossendorf 2011), but it was withdrawn in 2016 due to a lack of progress (Ossendorf 2016). We have reviewed and gained insights from this protocol.…”

Section: Introduction 6 Rationale: Describe the Rationale For The Rev...mentioning

confidence: 99%

Therapeutic vaccines for follicular lymphoma: a systematic review protocol

Zhelnov,

Suponin,

Potanin

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUNDObjectives: In this review we focus on the results of clinical trials of vaccination in follicular lymphoma, and discuss potential strategies to enhance the efficacy of immunotherapy in the future.METHODSEligibility criteria: We included any clinical randomized controlled trials of therapeutic antitumor vaccines in patients with histologically confirmed follicular lymphoma. Progression-free survival is the primary outcome.Information sources: We searched PubMed, Embase (through Ovid), Scopus, available Web of Science databases, and relevant and available study registries (PROSPERO, Cochrane CENTRAL, ClinicalTrials.gov through their own interfaces, and others through WHO International Clinical Trials Registry Platform Search Portal). We did not specifically search preprint servers due to exporting issues, but some of those were searchable through Ovid Embase. We also manually reviewed included reports for relevant references and searched for additional reports of included studies via Google and trial registers.Risk of bias: We will assess risks of bias across outcomes using RoB 2.0. We will also assess risks of publication bias across studies and bias due to missing evidence in a synthesis (ROB-ME).Synthesis of results: We will conduct fixed-effects model meta-analyses if patient and intervention characteristics are homogenous across included studies. If pooling is clinically inappropriate due to a mix of newly diagnosed with relapsed or refractory lymphoma or autologous and allogenic vaccines, we will summarize studies descriptively. Finally, we will assess the certainty of the evidence and produce GRADE Summary of Findings tables.OTHERFunding: This research was supported by the Russian Science Foundation under grant # 22-25-00516.Registration: This review will be registered in PROSPERO – please follow the project repository for updates: https://doi.org/10.17605/OSF.IO/KBZFWKey words: follicular lymphoma, non-Hodgkin lymphoma, vaccines, vaccination.License: This document is licensed under CC BY-SA 4.0.

show abstract

Section: Introduction 6 Rationale: Describe the Rationale For The Rev...mentioning

confidence: 99%